



Sundram Fasteners Limited

Email: investorshelpdesk@sfl.co.in

REGISTERED & CORPORATE OFFICE
98-A, VII FLOOR
DR. RADHAKRISHNAN SALAI,
MYLAPORE, CHENNAI - 600 004, INDIA
TELEPHONE: +91 - 44 - 28478500
FAX : +91 - 44 - 28478508 / 28478510
PAN : AAACS8779D
CIN : L35999TN1962PLC004943
WEBSITE : www.sundram.com

April 12, 2017

National Stock Exchange of India Limited

Scrip Code - SUNDRMFAST
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex
Bandra (East)
Mumbai - 400 051

By NEAPS

BSE Limited

Scrip Code - 500403
Corporate Relationship Department
1st Floor, New Trading Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai - 400 001

By Listing Centre

Dear Sir / Madam,

Compliance under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Notice of loss of share certificate – Folio No 9569

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement dated 11.04.2017 published in Economic Times with respect to Notice of loss of share certificate.

Thanking you,

Yours truly,
For SUNDRAM FASTENERS LIMITED

R Dilip Kumar
Vice President - Finance & Company Secretary



Intertek

ever to and passenger and cargo electric vehicle eSupro and sold over 1,100 units last year. "Overall, what we are doing in fleet as well as retail, we are expecting at least 3x increase in volume this year on various cars we have like the e20plus, eVerito and eSupro," he added.

"We are updating our tariff packs and will be soon introducing more exciting offers," Jio said on its website, but did not share any further details.

Experts said a fresh set of disruptive tariff packs from Jio would, typically, be aimed at offsetting any adverse impact of the company's 'Summer Surprise' offer recall on the

written to the Trai on Monday complaining that Jio had not withdrawn its 'Summer Surprise' offer and sought the regulator's immediate intervention.

In response, a Jio spokesman said the company "is pained to note such continued and deliberate attempt

Abbott Asks Patients in India to Report Adverse Effects of BVS


Divya.Rajagopal
@timesgroup.com

Mumbai: A week after US drug maker Abbott restricted the sale of its bioresorbable stents (BVS) in the European market, it has issued a notice in India asking patients and healthcare professionals to report any adverse effect that might be related with the use of this stent. BVS, used as an implant during an angioplasty procedure, is a tube device that clears blockages in arteries that carry blood to the heart which dissolves over time.

"Based on the three years clinical data analysis from ABSORB II, it has been observed that there is an over elevated rate of major adverse cardiac events, specifically myocardial infarction and scaffold thrombosis", the Drug Controller General of India said in a public notice. The decision comes after Abbott revealed in March this year that in a two-year study, there is an increased rate of major adverse cardiac events observed in patients receiving the BVS, when compared to patients treated with the approved (and widely used) drug-eluting stent. "Abbott notified the DCGI last week that post-marketing registries are being initiated in Europe to monitor implantation technique for Absorb.

The objective of the EU registries is similar to post-approval observational studies and training being conducted in other parts of the world to confirm the effect of current implantation technique on clinical outcomes," said an Abbott spokesperson in an email response to ET. "Absorb continues to be commercially available in Europe through the registries. Absorb is not being withdrawn from Europe and nothing has changed with the product's regulatory status," the company added.

The Indian drug regulator's decision is in tandem with other drug regulators like the



Bioresorbable stent (BVS)

HEALTH WISE

Decision comes after Abbott revealed that there is an increased rate of major adverse cardiac events observed in patients receiving the BVS

USFDA that has advised its patients who are put under BVS to report any cardiac symptoms such as irregular heartbeats, chest pain or shortness of breath to seek medical help.

Abbott's advisory comes at a time when the Indian pricing regulator slashed the prices of stents by over 75%.

The National Pharmaceutical Pricing Authority has capped the ceiling prices of Drug Eluting Stents (DES) and Bioresorbable Vascular Scaffolds (BVS) at ₹29,600 and Bare Metal Stents (BMS) at ₹7,260.

Including VAT, these stents are expected to cost ₹31,080 and ₹7,623 respectively. This had led to an uproar among stent manufacturers who said that such a move would kill innovation, and it was not taking into account the technological differentiation between two different types of stents. The NPPA regulator announced on Twitter that the regulator's idea that there was not much difference in a drug eluting and bioresorbable stent was vindicated with Abbott's new study results.

Sundram Fasteners Limited
 CIN: L35999TN1962PLC004943
 Registered office: 9B-A, VII Floor, Dr Radhakrishnan Salai, Mylapore, Chennai - 600 004
 Tel: +91 - 44 - 28478500 | Fax: 91 - 44 - 28478508 / 28478510
 Email: investorshelpdesk@sfl.co.in | Website: www.sundram.com

NOTICE OF LOSS OF SHARE CERTIFICATE

NOTICE is hereby given that the following share certificates issued by the Company registered in the name of person specified herein is reported to have been lost.

Folio No.	Registered Holder	Share Certificate Nos.	No. of Shares	Distinctive Numbers	
				From	To
9569	Ruffino D'Souza	409785	312	102760479	1027607
		417110	312	162221793	1622221

The Company shall proceed to issue the duplicate share certificates in favour of shareholder / claimant in lieu of the original share certificates in the absence of an objection with evidence lodged within 7 days of publication of this notice to the undersigned from any person claiming any interest, right or title to the shares specified above. The Company shall not entertain any claim thereafter. Any person dealing with the above said shares will be doing so at his own risk.

Chennai
10.04.2017

For Sundram Fasteners Limited
R Dilip Kumar
Vice President - Finance & Company Secretary

GFSU Gujarat Forensic Sciences University
 NAAC Accredited 'A' Grade
 Knowledge | Wisdom | Politeness

The World's First.
(A State University Estd. by Govt. of Gujarat, Recognized by UGC)

Launching First of its kind e-Learning Programme in Forensic Accounting

In collaboration with CDIMS, Mumbai

11th April, 2017 (at 11.30 am)
At GFSU, Campus, Sector-9, Gandhinagar

- **Course details:** 25 Modules on Conceptual and Advanced Knowledge of Forensic Accounting based on the case studies
- **Mode of Learning:** E Learning

Who can apply:

1. Professionals working in the fields of Auditing / Accounting / Banking / Insurance / Financial Services.
2. Graduates from any discipline.

Eligible candidates may register online from 11/04/2017 onwards.

For further details please visit:
<http://www.gfsu.edu.in/notice-board> or
www.chetandalal.com

Registrar

Economic Times
dt: 11.04.2017

